Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis
Mohamed Elsaid, Veterinary Surgeon at Canadian Veterinary Hospital, shared on LinkedIn:
”Hyperlipidemia in Cushing’s Syndrome and Its Role in Thrombogenesis
Hyperlipidemia is a common but often underestimated metabolic consequence of Cushing’s syndrome, and it plays a direct role in the development of thromboembolic disease.
Pathophysiology
Chronic hypercortisolism induces dyslipidemia through multiple mechanisms:
- Increased hepatic VLDL synthesis
- Enhanced lipolysis with redistribution of free fatty acids
- Reduced activity of lipoprotein lipase
- Insulin resistance contributing to altered lipid metabolism
This typically results in:
– Marked hypertriglyceridemia
– Elevated total cholesterol
– Lipemic or grossly turbid serum samples (as seen clinically)
– Link Between Hyperlipidemia and Thrombosis
Hyperlipidemia contributes to thrombogenesis by:
- Increasing blood viscosity
- Promoting endothelial dysfunction
- Enhancing platelet activation and aggregation
- Reducing fibrinolytic activity via increased PAI-1
- Upregulating procoagulant factors (Factors VIII, IX, XI)
These effects act synergistically with cortisol-induced:
Antithrombin III suppression
Decreased protein C and S activity
The result is a profound hypercoagulable state.
Clinical Implications
Patients with Cushing’s syndrome are predisposed to:
Venous thromboembolism (VTE)
Pulmonary thromboembolism
Microthrombi affecting renal, hepatic, and pulmonary perfusion
Hyperlipidemia should therefore be viewed as a pathologic contributor, not merely a biochemical abnormality.
Clinical Take-Home Messages
– Lipemic serum in Cushing’s patients is a red flag
– Routine lipid profiling should be part of endocrine case monitoring
– Thrombotic risk assessment is essential, especially in severe or untreated cases
– Early intervention may reduce morbidity and mortality.”
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation
-
Mar 16, 2026, 17:42Mohamed Sherif Salem: Turning 2026 KDIGO Complexity into Bedside Clarity
-
Mar 16, 2026, 17:39Julie Cardoso: What Happens to Venous Valves When a Blood Clot Forms?
-
Mar 16, 2026, 17:38Nasir Jamal: Blood Transfusion Criteria and Hemodialysis Thresholds in ESRD Patients
-
Mar 16, 2026, 17:37Octavio Cosín Sales: Understanding the Influence of Systemic Factors on Chronic Venous Insufficiency
-
Mar 16, 2026, 17:35Shiny K. Kajal: From Simple Calcium Chelation to Full-Blown Red Cell Metabolic Engineering